Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPR720 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Investigator Blind: Placebo | PLACEBO_COMPARATOR | Participants received SPR720 matching-placebo capsules, orally, once daily (QD) for 56 days. |
| Investigator Blind: SPR720 500 mg | EXPERIMENTAL | Participants received SPR720 500 mg (250 mg × 2) capsules along with 2 SPR720 matching- placebo capsules, orally, QD for 56 days. |
| Investigator Blind: SPR720 1000 mg | EXPERIMENTAL | Participants received SPR720 1000 mg (250 mg × 4) capsules, orally, QD for 56 days. |
| Open-label: SPR720 1000 mg | EXPERIMENTAL | Participants received SPR720 1000 mg (250 mg × 4) capsules, orally, QD for 56 days. |
| Open-label: SPR720 500 mg | EXPERIMENTAL | Participants received SPR720 500 mg (250 mg × 2) capsules, orally, twice daily (BID) for 56 days. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo-matching capsules was administered orally. |
| SPR720 500 mg | DRUG | SPR720 500 mg (250 mg × 2 capsules) was administered orally. |
| SPR720 1000 mg | DRUG | SPR720 500 mg (250 mg × 4 capsules) was administered orally. |
Inclusion Criteria: 1. Has a prior diagnosis of NTM-PD due to MAC according to American Thoracic Society (ATS) criteria 2. Has at least one prior lower respiratory culture (sputum or bronchoalveolar lavage \[BAL\]) positive for MAC in the 12 months prior to consent 3. Has an induced sputum culture ...
SPR720 is an investigational oral small molecule being developed by Spero Therapeutics, Inc. for nontuberculous mycobacterial pulmonary disease (NTM-PD), a chronic lung infection. It is in Phase 2 clinical development and has not been approved by the FDA. It is also referred to as SPR720 500 mg.
SPR720 is being developed to treat nontuberculous mycobacterial pulmonary disease (NTM-PD), specifically Mycobacterium avium complex (MAC) pulmonary disease. The Phase 2 trial enrolled adults with this condition. SPR720 is investigational and has not been approved for any indication.
SPR720 targets DNA gyrase B, a bacterial enzyme involved in DNA replication. By inhibiting this target, SPR720 is designed to interfere with mycobacterial DNA processes. DNA gyrase B is a protein target, and SPR720 is a small molecule therapeutic.
SPR720 is being developed by Spero Therapeutics, Inc., which trades under the ticker SPRO. The company is the sponsor of the clinical program evaluating SPR720 in nontuberculous mycobacterial pulmonary disease.
SPR720 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The completed Phase 2 trial evaluated its efficacy, safety, tolerability, and pharmacokinetics in patients with Mycobacterium avium complex pulmonary disease.
SPR720 has been studied in one Phase 2 trial, NCT05496374, titled a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SPR720 compared with placebo for Mycobacterium avium complex pulmonary disease. The trial was completed, enrolled 25 participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United States.